Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 14/20 | 0.59 |
| ▸ | CDK2 | P24941 | 14/20 | 0.59 |
| ▸ | FLT3 | P36888 | 14/20 | 0.59 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4708842 | 0.88 | CCNE1 (0.70) | CCNE1CDK2FLT3KIT | |
| SCHEMBL3010145 | 0.87 | CCNE1 (0.69) | CCNE1CDK2FLT3KIT | |
| SCHEMBL3618938 | 0.84 | FLT3 (0.62) | CCNE1CDK2FLT3KITBTK | |
| SCHEMBL3024595 | 0.83 | CCNE1 (0.67) | CCNE1CDK2FLT3KIT | |
| SCHEMBL3024597 | 0.83 | CCNE1 (0.67) | CCNE1CDK2FLT3KIT | |
| SCHEMBL3017522 | 0.82 | CCNE1 (0.61) | CCNE1CDK2FLT3KITBTK | |
| SCHEMBL3017516 | 0.82 | CCNE1 (0.61) | CCNE1CDK2FLT3KITBTK | |
| SCHEMBL3779575 | 0.82 | CCNE1 (0.47) | CCNE1CDK2FLT3KIT | |
| SCHEMBL3779569 | 0.82 | CCNE1 (0.47) | CCNE1CDK2FLT3KIT | |
| SCHEMBL3014838 | 0.82 | FLT3 (0.67) | CCNE1CDK2FLT3KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723336-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP3K3, MAP3K2, MAP4K3 | CCNE1 538/4885CDK2 67/4885FLT3 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.